✦ LIBER ✦

Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study

✍ Scribed by Fritz H. Schröder; Bertrand Tombal; Kurt Miller; Laurent Boccon-Gibod; Neal D. Shore; E. David Crawford; Judd Moul; Tine Kold Olesen; Bo-Eric Persson

Book ID: 109056245
Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 392 KB
Volume: 106
Category: Article
ISSN: 1464-4096
DOI: 10.1111/j.1464-410x.2009.08981.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Changes in alkaline phosphatase levels i

Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study

✍ Fritz H. Schröder; Bertrand Tombal; Kurt Miller; Laurent Boccon-Gibod; Neal D. S 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 392 KB

Study Type – Therapy (RCT) Level of Evidence 1b ## OBJECTIVE To compare the activity of degarelix, a new gonadotrophin‐releasing hormone (GnRH) blocker, with leuprolide depot 7.5 mg in the control of total serum alkaline phosphatase (S‐ALP) levels in patients with prostate cancer. ## PATIENTS AND

The efficacy and safety of degarelix: a

The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer

✍ Laurence Klotz; Laurent Boccon-Gibod; Neal D. Shore; Cal Andreou; Bo-Eric Persso 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 305 KB